Remove 2025 Remove Hypertension Remove Strokes
article thumbnail

FDA Approves Updated Label for Tryvio (aprocitentan)

DAIC

tim.hodson Wed, 04/09/2025 - 14:38 April 9, 2025 Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced March 17, 2025 ), has now approved the updated label for Tryvio(aprocitentan). Hypertension.

article thumbnail

Association of Duration of Recognized Hypertension and Stroke Risk: The REGARDS Study

Stroke Journal

Stroke, Volume 56, Issue 1 , Page 105-112, January 1, 2025. BACKGROUND:The focus for reducing hypertension-related cardiovascular disease is the management of blood pressure. Participants were stratified by duration of recognized hypertension: normotensive (0 years), 5 years, 6 to 20 years, or 21+ years.

article thumbnail

Abstract WP402: Hypertension-linked oxidative stress and inflammatory transcriptomic pathways in the brain cortical regions of a rat model following ischemic stroke

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page AWP402-AWP402, February 1, 2025. Background:Patients with hypertension (HTN) are almost 3 times more likely to have a stroke than non-hypertensive individuals. fold), and TNF superfamily member 7 (14-fold) as compared to normotensive SD rats without stroke.

article thumbnail

Abstract TP21: Efficacy and Safety of Sacubitril/Valsartan in Patients with Acute Ischemic Stroke and Hypertension within 24-72 hours

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP21-ATP21, February 1, 2025. IntroductionThe efficacy of blood pressure (BP) reduction of Sacubitril/valsartan has been proved in hypertension patients, yet not in patients with acute ischemic stroke (AIS).

article thumbnail

Abstract TP136: STRACK: A Continuum of Stroke Care, Improving Post-Stroke and Cardiometabolic Patient Outcomes

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP136-ATP136, February 1, 2025. Once these post-stroke patients have been identified, they are given a personalized monitoring plan depending on the individuals risk factors, the personalized care and rehabilitation plans are tracked and followed.

Stroke 40
article thumbnail

Abstract TP334: Racial Disparities in Functional Outcomes and Stroke Recurrence in Young Patients with Ischemic Stroke

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP334-ATP334, February 1, 2025. Introduction:Studies have reported racial disparities in acute stroke treatment and follow-up care in young patients which lead to less desirable outcomes for minorities. of young patients had 1 follow-ups at stroke clinic. male, covering 57.2%

Stroke 40
article thumbnail

Abstract DP50: Angiotensin inhibition reduces the risk of subarachnoid hemorrhage in patients with hypertension

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ADP50-ADP50, February 1, 2025. million patients with hypertension were assessed. However, patients on non-ACEI/ARBs anti-hypertensive medications had a similar risk of SAH risk compared to those not on any antihypertensives [HR:1.00(0.97-1.04), million,follow-up:6.3 female) [HR:0.94(0.91-0.97),